Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a bridging study in Japan for HANSIZHUANG, combined with chemotherapy, targeting extensive-stage small cell lung cancer. This study aims to support the future marketing application of HANSIZHUANG in Japan, following successful international trials. The company is advancing multiple clinical studies globally, enhancing its position in the oncology market.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative monoclonal antibodies. The company’s primary product, HANSIZHUANG, is an anti-PD-1 monoclonal antibody approved for various cancer treatments, including lung and esophageal cancers, across multiple regions such as China, the European Union, and Southeast Asia.
Average Trading Volume: 1,425,030
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.09B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.